Clinical Trial Update: TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers [Phase 1]

View source ↗

Summary

This Phase 1 safety study evaluated oral solutions of TMC435350 at 100, 200 or 400 mg (equivalent) versus placebo in healthy Japanese male volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435350

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HCV | Phase 1 | Status: COMPLETED